Companies / NXN

NEXSEN LIMITED

ASX:NXNPharmaceuticals, Biotechnology & Life Sciences
200.2M shares on issueASX (delayed) · as of 28 July 2026$0.28price · delayed$58.1Mmarket cap · indicative
C
Dilution gradeprovisional — limited history

Runway 2–4 quarters; share count grew 18% in 24 months; options/rights overhang 12% of shares

Cash runway2.7 quarters of funding
Share-count growth (24m)18.1%
Raise cadence (24m)0 cash raises
Options & rights overhang12.0% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

NEXSEN LIMITED's ordinary share count was 93M as of February 2026, an 18.1% increase between February 2026 and February 2026. The company did not raise capital in the past 24 months according to disclosed raises. Options and rights on issue could convert into 24M new shares, equal to 12.0% of the current share count, with 0% in the money and the nearest expiry in October 2028. At the March 2026 quarter the company reported A$3.9M in available cash, equivalent to 2.7 quarters of cover at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
12.0%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
2.7 qtrs
Cash cover · 2–4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 200.2M per ASX (delayed) (28 July 2026).
199.4M200.2M201.0MOct 25Mar 26July 26

Cash runway

2.7 qtrs
Two to four quarters of funding at the recent spend rate.
$3.9M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 2 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
24 Feb 20262A · quoted issueNXN : ORDINARY FULLY PAID92.8MAppendix 2A
5 Feb 20262A · quoted issueNXN : ORDINARY FULLY PAID78.6MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

No equity raises in the last 24 months.
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

12.0%
Total overhang · of current shares
0.0%
In the money · at current price
24.0M
Potential new shares
Oct 2028
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

No director dealing notices (Appendix 3Y) on record.
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

22 July 2026Launch of Hong Kong facility & pipeline expansion
29 June 2026Global Healthcare CEO Joins Nexsen Advisory Board
24 June 2026$P$1.5m non-dilutive ARC funding for manufacturing
15 May 2026Becoming a substantial holder
12 May 2026$PNexsen secures first hospital partner in Asia
3 May 2026$PNexsen and Universiti Malaya launch joint facility
27 Apr 2026$PQuarterly Report - Q3 FY26
6 Apr 2026$PQMS milestone achieved
30 Mar 2026$PHK$6 million grant awarded to advance Asia-Pacific execution
25 Mar 2026$PNexsen accelerates global rollout for StrepSure
22 Mar 2026$PFDA feedback derisks US approval pathway for StrepSure
26 Feb 2026$PHalf Yearly Report and Accounts
26 Feb 2026Change in substantial holding - Nexsen
24 Feb 2026Nexsen highlights GBS strategy at ISSAD 2026
24 Feb 2026Application for quotation of securities - NXN
5 Feb 2026Change in substantial holding - Nexsen
5 Feb 2026Application for quotation of securities - NXN
29 Jan 2026$PQuarterly Report - Q2 FY26
26 Jan 2026$P$500k govt grant expands GBS project to neonates
23 Jan 2026Notice under ASX Listing Rule 3.10A

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.